glp 1 rezeptor antagonist Trends in the Development of GLP-1 Receptor Agonists Emerging Role of GLP-1 Receptor
Description
Semaglutide and tirzepatide reduced blood glucose by ~200 mg/dL and HbA1c by ~2% at 2 months, but their effects waned by the third month
The trial used a 20-week bi-weekly dose escalation phase followed by a 26-week maintenance phase, for a total of 46 weeks
Discoveries like this simply would not exist without our research participants
Todo esto posibilita que reduczamos tus gastos
T.LinS.et al (2020)
Diabetes 58 McCleanP.HlscherC
